Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

88th European Atherosclerosis Society Congress – Virtual meeting

4-7 October, 2020

More from ORION with inclirisan, siRNA therapeutic targeting the liver

More from ORION with inclirisan, siRNA therapeutic targeting the liver

EAS2020 reported new data for the efficacy of inclisiran in high-risk primary prevention patients from ORION 11. There were also findings from ORION-9 in heterozygous FH patients (1,2). ORION-11: Inclisiran is effective in high-risk primary prevention patients The ORION-11 study included 1,617 patients with either established…

read more »
Long-term data with LIB003: where next for this PCSK9 inhibitor?

Long-term data with LIB003: where next for this PCSK9 inhibitor?

LIB003, a novel PCSK9 inhibitor given as a small volume monthly injection, was efficacious and well tolerated over 52 weeks. The results were reported at EAS2020- Virtual, 4-7 October (1). LIB003 is a recombinant fusion drug which combines a PCSK9-binding domain (adnectin) that blocks interaction…

read more »
Evinacumab – answering an unmet need in homozygous FH?

Evinacumab – answering an unmet need in homozygous FH?

A post hoc analysis from the ELIPSE HoFH study shows that homozygous familial hypercholesterolaemia (FH) patients with null LDLR mutations obtain about 50% reduction in LDL cholesterol on top of other therapy. The results were reported at EAS2020- Virtual, 4-7 October (1). Management of homozygous…

read more »